Allakos Inc (ALLK)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Robert Alexander |
| Employees: | 190 |
| Web site: | allakos.com |
|
825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS, CA, 94070
650-597-5002
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Allakos Inc. develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of gastritis and/or eosinophilic duodenitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.
Please log in first to see chart